We’re proud to celebrate a major milestone for Sesh Incorporated, an EvoNexus Portfolio Company: A 1st-place finish at the 2026 SDSU San Diego Angel Conference (SDAC), held on May 29, 2026.
SDAC is a program dedicated to empowering both early-stage founders and accredited investors through rigorous training, meaningful mentorship, and high-quality deal flow. This year’s conference brought together finalist companies to pitch before Fund VIII investors, with at least $200,000 in investment available for one or more of the most promising startups.
Leading Sesh Incorporated through this competition was founder Dr. Andrew Sinkoe, supported by EvoNexus Mentors Dr. Gene Dantsker, Dr. Michael Hill, Dr. Mike Benchimol, and Dr. Scott Lippman. Their guidance helped Andrew sharpen his presentation, refine his story, and arrive ready to compete at the highest level. EvoNexus Executives in Residence Dr. Dantkser and Dr. Hill have been Lead Mentors of Sesh since the company’s admission to the incubator in October 2025.
“We at EvoNexus couldn’t be more proud of Sesh, the personalized oncology company that’s going to save lives. We assigned Dr. Andrew Sinkoe a world class mentorship team with deep domain expertise that meets with him regularly, as Sesh moves from brilliant technology to a marketable product and a fundable company. Andrew and Sesh have grown by leaps as attested by increasing grant awards and now this investment by SDAC.” – Dr. Gene Dantsker, EvoNexus Executive in Residence.
At EvoNexus, we back founders who are relentlessly focused on building real companies that solve real problems. Seeing Sesh earn recognition from a room filled with experienced investors and winning the competition that had 138 contestants, from both within and outside the San Diego region, was validation of the venture’s mission.
Winning 1st place in that environment carries real weight. We’re also proud to note that fellow EvoNexus portfolio company PolyVascular also earned a spot among the top a six finalists. Congratulations to Andrew Sinkoe, Gene Dantsker, Michael Hill, and the entire Sesh Incorporated team. We can’t wait to see what comes next.
About Sesh:
Improving Treatment Outcomes for Cancer Patients by pioneering liquid biopsy technology to select the correct personalized immunotherapy treatment.
Learn more at oncologysesh.com
About EvoNexus:
EvoNexus is California’s leading nonprofit technology startup incubator, with locations in San Diego and Southern California. Since its formation in 2010, EvoNexus has successfully built 288 companies with an exceptional survival rate of over 85%. EvoNexus portfolio companies have secured over $2.4B in cumulative venture funding and achieved 62 acquisitions, alongside 1 successful IPO. Backed by an elite network of global corporate partners, EvoNexus continues to drive massive economic impact, culminating in a record-breaking year with $619M raised in 2025 alone.
